Matches in SemOpenAlex for { <https://semopenalex.org/work/W2470129665> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2470129665 endingPage "59" @default.
- W2470129665 startingPage "59" @default.
- W2470129665 abstract "A large proportion of the global population is affected by chronic inflammatory disorders, including atherosclerosis, type 2 diabetes and obesity, but the treatment options for these conditions are limited. Virtually, all chronic inflammatory disorders are associated with the excess production of interleukin-1β (IL-1β). IL-1β initiates and enhances inflammatory responses, hence, the production of bioactive IL-1β is normally tightly regulated at multiple levels: IL-1β is initially produced as an inactive precursor molecule that undergoes cleavage to produce bioactive IL-1β. While the bioactive cytokine can be secreted very rapidly, cleavage of IL-1β is the critical and rate-limiting step in driving inflammatory responses. Cleavage of IL-1β is mediated by a caspase-1-activating complex known as the ‘inflammasome’. Several different types of inflammasome have been described, among which the inflammasome that contains NLRP3 represents the most promising therapeutic target for disrupting IL-1β production and restricting subsequent inflammatory pathology. NLRP3 proteins are normally maintained in an auto-suppressive state, but upon activation by diverse stimuli, NLRP3 proteins bind to the ASC adaptor via a homotypic PYD interaction and ASC recruits pro-caspase-1 to initiate IL-1β processing and release. Genetic deletion of NLRP3 abrogates inflammasome signaling and ablates IL-1β release by immune cells. We designed mimetic peptides that disrupt PYD-PYD interactions between NLRP3 and ASC. The ability of human macrophages to take up FAM-labeled peptides was assessed by flow cytometry. Peptide suppression of the NLRP3/ASC interaction was evaluated as the ability to impair the release of bioactive IL-1β from human macrophages exposed to NLRP3-specific stimuli (monosodium urate crystals, ATP). This proof-of-concept study allowed us to evaluate the therapeutic potential of inhibitory peptides for disrupting immune cell function in inflammatory diseases." @default.
- W2470129665 created "2016-07-22" @default.
- W2470129665 creator A5012542550 @default.
- W2470129665 creator A5045760818 @default.
- W2470129665 creator A5062000015 @default.
- W2470129665 date "2014-11-01" @default.
- W2470129665 modified "2023-09-28" @default.
- W2470129665 title "132" @default.
- W2470129665 doi "https://doi.org/10.1016/j.cyto.2014.07.139" @default.
- W2470129665 hasPublicationYear "2014" @default.
- W2470129665 type Work @default.
- W2470129665 sameAs 2470129665 @default.
- W2470129665 citedByCount "0" @default.
- W2470129665 crossrefType "journal-article" @default.
- W2470129665 hasAuthorship W2470129665A5012542550 @default.
- W2470129665 hasAuthorship W2470129665A5045760818 @default.
- W2470129665 hasAuthorship W2470129665A5062000015 @default.
- W2470129665 hasConcept C139964883 @default.
- W2470129665 hasConcept C151730666 @default.
- W2470129665 hasConcept C164027704 @default.
- W2470129665 hasConcept C175156509 @default.
- W2470129665 hasConcept C185592680 @default.
- W2470129665 hasConcept C203014093 @default.
- W2470129665 hasConcept C2776914184 @default.
- W2470129665 hasConcept C2777209026 @default.
- W2470129665 hasConcept C2778690821 @default.
- W2470129665 hasConcept C2908647359 @default.
- W2470129665 hasConcept C43369102 @default.
- W2470129665 hasConcept C71924100 @default.
- W2470129665 hasConcept C74172505 @default.
- W2470129665 hasConcept C86803240 @default.
- W2470129665 hasConcept C8891405 @default.
- W2470129665 hasConcept C95444343 @default.
- W2470129665 hasConcept C99454951 @default.
- W2470129665 hasConceptScore W2470129665C139964883 @default.
- W2470129665 hasConceptScore W2470129665C151730666 @default.
- W2470129665 hasConceptScore W2470129665C164027704 @default.
- W2470129665 hasConceptScore W2470129665C175156509 @default.
- W2470129665 hasConceptScore W2470129665C185592680 @default.
- W2470129665 hasConceptScore W2470129665C203014093 @default.
- W2470129665 hasConceptScore W2470129665C2776914184 @default.
- W2470129665 hasConceptScore W2470129665C2777209026 @default.
- W2470129665 hasConceptScore W2470129665C2778690821 @default.
- W2470129665 hasConceptScore W2470129665C2908647359 @default.
- W2470129665 hasConceptScore W2470129665C43369102 @default.
- W2470129665 hasConceptScore W2470129665C71924100 @default.
- W2470129665 hasConceptScore W2470129665C74172505 @default.
- W2470129665 hasConceptScore W2470129665C86803240 @default.
- W2470129665 hasConceptScore W2470129665C8891405 @default.
- W2470129665 hasConceptScore W2470129665C95444343 @default.
- W2470129665 hasConceptScore W2470129665C99454951 @default.
- W2470129665 hasIssue "1" @default.
- W2470129665 hasLocation W24701296651 @default.
- W2470129665 hasOpenAccess W2470129665 @default.
- W2470129665 hasPrimaryLocation W24701296651 @default.
- W2470129665 hasRelatedWork W2103516372 @default.
- W2470129665 hasRelatedWork W2154575744 @default.
- W2470129665 hasRelatedWork W2172732242 @default.
- W2470129665 hasRelatedWork W2402154334 @default.
- W2470129665 hasRelatedWork W2549780172 @default.
- W2470129665 hasRelatedWork W2888676321 @default.
- W2470129665 hasRelatedWork W3003308701 @default.
- W2470129665 hasRelatedWork W3007908201 @default.
- W2470129665 hasRelatedWork W3017248443 @default.
- W2470129665 hasRelatedWork W3031630899 @default.
- W2470129665 hasVolume "70" @default.
- W2470129665 isParatext "false" @default.
- W2470129665 isRetracted "false" @default.
- W2470129665 magId "2470129665" @default.
- W2470129665 workType "article" @default.